C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on April 29, 2024 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
马萨诸塞州沃特敦，2024年4月29日（GLOBE NEWSWIRE）——致力于推进靶向蛋白降解科学的临床阶段生物制药公司C4 Therapeutics, Inc.（C4T）（纳斯达克股票代码：CCCC）今天宣布，在公司董事会组织、领导和薪酬委员会任职的独立董事批准授予购买146,880股股票的非合格股票期权公司向一名新员工发放普通股（“激励补助金”），补助金于2024年4月29日（“授予日期”）发放。根据纳斯达克上市规则5635（c）（4），激励补助金是作为物质诱因发放的，是激励该个人在C4T工作。
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T's common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee's start date, with the remainder of the shares vesting in twelve equal quarterly installments thereafter, subject to the employee's continued employment with C4T through each vesting date.
激励补助金的每股行使价等于C4T普通股在授予日的收盘价。激励补助金将在四年内归属，其中 25% 的股份将在员工入职一周年之际归属，其余股份将分十二个等额的季度分期归属，前提是员工在每个归属日之前继续在C4T工作。
About C4 Therapeutics
关于 C4 疗法
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
C4 Therapeutics（C4T）（纳斯达克股票代码：CCCC）是一家临床阶段的生物制药公司，致力于兑现靶向蛋白质降解科学的承诺，创造改变患者生活的新一代药物。C4T正在通过临床研究和利用其TORPEDO推进靶向肿瘤学项目 该平台可高效设计和优化小分子药物，以解决难以治疗的疾病。C4T的降解剂药物旨在利用人体的天然蛋白质回收系统快速降解致病蛋白，从而有可能克服耐药性、不可药物靶标和改善患者预后。欲了解更多信息，请访问 www.c4therapeutics。
Contacts:
联系人：
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
投资者：
考特尼·索尔伯格
投资者关系高级经理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒体：
洛兰·斯普林
企业传播与患者宣传高级董事
LSpreen@c4therapeutics.com
